| Document Date: 2014-10-01 21:56:23
Open Document File Size: 94,20 KBShare Result on Facebook
Company The PBAC / AbbVie Pty Ltd / ITT / / Country United States / Australia / / Currency USD / / Event FDA Phase / / MedicalCondition particularly upper respiratory tract infections / severe psoriasis / opportunistic infections / disease / plaque psoriasis / serious infections / moderate plaque psoriasis / severe plaque psoriasis / moderate chronic plaque psoriasis / severe chronic plaque psoriasis / moderate whole-body chronic plaque psoriasis / psoriasis / REVEAL Psoriasis / infection / moderate disease / severe disease / infectious adverse events / tuberculosis / / MedicalTreatment biologic therapies / retreatment / phototherapy / biological therapy / / Organization Listing Requested and PBAC’s View Authority / / Position evaluator / Trial ID/ First Protocol title/ Publication title author / Trial ID/ First author / / Product Humira / cyclosporine / AB140 / M02-528 / / Technology et al Reich et al Saurat et al Navarini et al Protocol / Saurat et al Protocol / antibodies / et al Poulin et al Papp et al Strober et al Protocol / /
SocialTag |
Microsoft Word[removed]Adalimumab Abbvie PSD March 2013 FINAL .docx